Nuvalent
activity induced intracranial responses in patients with refractory alk phase refractory complete response alk fusion partial response alk fusion no known resistance mutations lines of therapy including and chemotherapy complete resolution of parietal parenchymal brain metastases after weeks treatment continues at months ongoing confirmed weeks weeks alk fusion resistance mutation lines of therapy consisting of and after weeks treatment continues at months ongoing confirmed courtesy of and hospital vall barcelona courtesy of university united states data as of august central nervous system complete response non small source lin cell lung cancer partial resp once daily tyrosine kinase inhibitor | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
April 2024
Slide
22 of 42
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
February 2024
activity induced intracranial responses in patients with refractory alk phase refractory complete response alk fusion alk fusion no known resistance mutations lines of therapy including and chemotherapy complete resolution of parietal parenchymal brain metastases after weeks treatment continues at months ongoing mutation weeks resistance alk fusion partial response ongoing confirmed lines of therapy consisting treatment continues at after weeks of and months weeks confirmed courtesy of and hospital vall barcelona courtesy of university united states data as of august central nervous system complete response non small source lin cell lung cancer partial response once daily tyrosine kinase inhibitor | Nuvalent
Investor Presentation
January 2024
activity induced intracranial responses in patients with refractory alk phase refractory complete response alk fusion partial response alk fusion no known resistance mutations lines of therapy including and chemotherapy complete resolution of parietal parenchymal brain metastases after weeks treatment continues at months ongoing confirmed weeks weeks alk fusion resistance mutation lines of therapy consisting of and after weeks treatment continues at months ongoing confirmed courtesy of and hospital vall barcelona courtesy of university united states data as of august central nervous system complete response non small cell lung cancer partial response once daily tyrosine kinase inhibitor source lin | Nuvalent
Investor Presentation
January 2024
activity induced intracranial responses in patients with refractory alk phase refractory complete response alk fusion partial response alk fusion no known resistance mutations lines of therapy including and chemotherapy complete resolution of parietal parenchymal brain metastases after weeks treatment continues at months ongoing confirmed weeks weeks alk fusion resistance mutation lines of therapy consisting of and after weeks treatment continues at months ongoing confirmed courtesy of and hospital vall barcelona courtesy of university united states data as of august central nervous system complete response non small cell lung cancer partial response once daily tyrosine kinase inhibitor source lin i | Nuvalent
Investor Presentation
November 2023
activity induced intracranial responses in patients with refractory alk | Nuvalent
Related slides by other companies
Ocado
Investor Day
May 2022
delivering attractive returns | Ocado
Oculis
Investor Presentation
April 2023
current treatment paradigm leaves two patient segments and losing vision us patient population million | Oculis
Ada Health
Other
June 2018
male search findings decreased obstructive ventilation pattern pathological respiratory sounds peak expiratory flow rate decreased rhonchi on auscultation wheezing on auscultation nam heat intolerance more than one year reduced exercise fatigue level result elevated dyspepsia indigestion time since onset one week to one month repeat consult yes diarrhea time since onset one week to one month malaise time since onset one week to one month myalgia dyspnea repeat consult yes time since onset more than one year severity exercise flatulence dairy products no effect time since onset one week to one search conditions most probable asthma chronic hepatitis non small cell lung related disease schistosomiasis chronic hypersensitivity pneumonitis cases | Ada Health
Aeglea BioTherapeutics
Investor Presentation
August 2020
demonstrates durable clinical response at week analysis | Aeglea BioTherapeutics
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io